2025年全球前列腺癌核子醫學診斷市場報告

前列腺癌核醫學診斷藥物的市場規模預計在未來幾年將快速成長。到 2029 年，這一數字將成長至 17.1 億美元，年複合成長率（CAGR）為 14.6%。預測期內的成長歸因於前列腺癌盛行率的上升、正子斷層掃描需求的增加、對環境永續性的認知的增強、癌症發生率的上升以及數位轉型的進步。預測期內的關鍵趨勢包括產品創新、技術進步、核醫學成像的進步、放射性藥物和成像方法的改進以及創新放射性藥物。

前列腺癌盛行率的不斷上升預計將推動前列腺癌核醫學診斷市場的成長。攝護腺癌是一種始於攝護腺的癌症。前列腺是男性體內的一個小的核桃形腺體，負責產生精液，即滋養和運輸精子的液體。前列腺癌患者的增加被認為是由於老化、生活方式改變和遺傳傾向等因素造成的。前列腺癌的核子醫學診斷提供了關鍵見解，幫助醫療保健提供者為前列腺癌患者提供更精確、有效和更有針對性的治療。例如，2024年2月，瑞士世界衛生組織（WHO）預測，2050年，全球癌症新病例將超過3,500萬，較2022年預計的2,000萬增加77%。因此，攝護腺癌盛行率的上升正在推動攝護腺癌核醫學診斷藥物市場的發展。

前列腺癌核醫診斷領域的主要企業正在積極創新影像技術並獲得美國食品藥物管理局（FDA）的批准。 FDA 的批準確保醫療保健提供者和患者能夠獲得一系列醫療狀況的安全有效的診斷測試。例如，2022年3月，瑞士製藥公司諾華推出Pluvicto（镥Lu 177 vipivotide tetraxetan），用於治療診斷為表達前列腺特異性膜抗原陽性（PSMA陽性）的去勢抗性前列腺癌（mCRPC）的成年患者。 Pluvicto 將標靶化合物（配體）與治療性放射性同位素結合，為表達 PSMA 的前列腺癌細胞提供精確的癌症治療。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場 - 宏觀經濟情景，包括利率、感染疾病、地緣政治、新冠疫情、經濟復甦對市場的影響

第5章 全球成長分析與策略分析框架

• 全球攝護腺癌核醫診斷PESTEL分析（政治、社會、科技、環境、法律因素、促進因素與限制因素）
• 最終用途產業分析
• 全球前列腺癌核子醫學診斷劑市場：成長率分析
• 全球前列腺癌核醫診斷市場表現：規模與成長，2019-2024
• 全球前列腺癌核醫診斷市場預測：規模與成長，2024-2029年，2034年
• 前列腺癌核診斷的全球總目標市場（TAM）

第6章市場區隔

• 全球前列腺癌核醫診斷市場：依類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
• 單光子發射電腦斷層掃描（SPECT）
• 光子發射電腦斷層掃描（PET）
• 全球前列腺癌核醫診斷市場（依檢測類型、表現及預測）2019-2024 年、2024-2029 年、2034 年
• 初步測試
• 確認檢查
• 全球前列腺癌核醫診斷市場：依最終使用者、績效及預測，2019-2024 年、2024-2029 年、2034 年
• 醫院
• 診所
• 其他最終用戶
• 全球前列腺癌核子醫學診斷市場、SPECT（單光子發射電腦斷層掃描）細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
• 伽馬攝影機SPECT
• 混合 SPECT 或 CT 影像
• 全球前列腺癌核醫診斷市場按正子斷層掃描 (PET) 型細分，績效及預測，2019-2024 年、2024-2029 年、2034 年
• PET 或 CT 影像
• PET 或 MRI 影像

第7章 區域和國家分析

• 全球前列腺癌核醫診斷市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
• 全球前列腺癌核醫診斷藥物市場：依國家、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

• 前列腺癌核子醫學診斷劑市場：競爭格局
• 前列腺癌核醫診斷市場：公司簡介
  • Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
  • General Electric Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

• GE Healthcare
• Lantheus
• CURIUM PHARMA
• Telix Pharmaceuticals Ltd.
• Eckert & Ziegler AG
• Point Biopharma Global Inc.
• Point Biopharma
• Alliance Medical Ltd.
• SHINE Medical Technologies LLC
• PETNET Solution
• NorthStar Medical Radioisotopes LLC
• Global Medical Solutions LLC
• Isotope Technologies Garching（ITG）
• Jubilant Pharma Limited
• Blue Earth Diagnostics Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

• 2029年攝護腺癌核醫診斷市場：提供新機會的國家
• 2029年前列腺癌核醫診斷市場：細分領域帶來新機會
• 前列腺癌核醫診斷市場2029年：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第36章 附錄

Prostate cancer nuclear medicine diagnostics involve the utilization of radioactive substances to detect and assess prostate cancer. These diagnostics play a crucial role in the detection, staging, and management of prostate cancer by providing comprehensive functional information regarding the disease's extent and characteristics. The process entails introducing radioactive substances (radiopharmaceuticals) into the body, typically through injection, which emit gamma rays or positrons.

The primary types of prostate cancer nuclear medicine diagnostics include single photon emission computed tomography (SPECT) and positron emission tomography (PET). Single photon emission computed tomography (SPECT) is a nuclear imaging technique that generates detailed three-dimensional images depicting the body's functional processes. These diagnostics encompass various test types, including preliminary and confirmatory tests, and are utilized by various end-users such as hospitals, clinics, and others.

The prostate cancer nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer nuclear medicine diagnostics market statistics, including prostate cancer nuclear medicine diagnostics industry global market size, regional shares, competitors with a prostate cancer nuclear medicine diagnostics market share, detailed prostate cancer nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the prostate cancer nuclear medicine diagnostics industry. This prostate cancer nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $0.86 billion in 2024 to $0.99 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. The growth in the historic period can be attributed to increasing demand for pet scans, increasing urbanization, rise in disposable income, rise in need for accurate cancer diagnosis, increasing emphasis on early detection.

The prostate cancer nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.71 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to rising prevalence of prostate cancer, increasing demand for positron emission tomography, rising awareness about environmental sustainability, rising frequency of cancers, increasing digital transformation. Major trends in the forecast period include product innovation, technological advancements, advancements in nuclear medicine imaging, improved radiopharmaceuticals and imaging methods, innovative radiopharmaceuticals.

The increasing prevalence of prostate cancer is expected to drive the growth of the prostate cancer nuclear medicine diagnostics market. Prostate cancer is a type of cancer that develops in the prostate, a small, walnut-shaped gland in men responsible for producing seminal fluid that nourishes and transports sperm. The rise in prostate cancer cases can be attributed to factors such as an aging population, lifestyle changes, and genetic predisposition. Prostate cancer nuclear medicine diagnostics offer critical insights that allow healthcare providers to deliver more accurate, effective, and tailored treatment for patients with prostate cancer. For example, in February 2024, the World Health Organization, a Switzerland-based agency specializing in global public health, projected that by 2050, there will be over 35 million new cancer cases, a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing prevalence of prostate cancer is driving the market for prostate cancer nuclear medicine diagnostics.

Key players in the prostate cancer nuclear medicine diagnostics sector are actively innovating diagnostic imaging technologies and securing approvals from the US Food and Drug Administration (FDA). FDA clearance ensures healthcare providers and patients have access to safe and effective diagnostic tests for various medical conditions. For example, in March 2022, Novartis, a Swiss pharmaceutical company, introduced Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) that expresses prostate-specific membrane antigen-positive (PSMA-positive). Pluvicto combines a targeting compound (ligand) with a therapeutic radioisotope, delivering precise cancer treatment to prostate cancer cells expressing PSMA.

In March 2023, Life Healthcare Group, a South African healthcare company, acquired TheraMed Nuclear to enhance its diagnostic imaging services, particularly in detecting and treating diseases such as organ dysfunction and cancer. TheraMed Nuclear, based in South Africa, specializes in prostate cancer nuclear medicine diagnostics.

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, General Electric, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, CURIUM PHARMA, Telix Pharmaceuticals Ltd., Eckert & Ziegler AG, Point Biopharma Global Inc., Point Biopharma, Alliance Medical Ltd., SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC, Isotope Technologies Garching (ITG), Jubilant Pharma Limited, Blue Earth Diagnostics Inc., Institute of Isotopes Co. Ltd., Radiopharm Theranostics, Bracco Diagnostic Inc., NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2024. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate cancer nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The prostate cancer nuclear medicine diagnostics market includes revenues earned by entities by bone scans, prostate-specific membrane antigen (PSMA) PET scan, bone scintigraphy, and CT scans. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer nuclear medicine diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Single Photon Emission Computed Tomography (SPECT); Photon Emission Computed Tomography (PET)
• 2) By Test Type: Preliminary Tests; Confirmatory Tests
• 3) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Single Photon Emission Computed Tomography (SPECT): Gamma Camera SPECT; Hybrid SPECT Or CT Imaging
• 2) By Positron Emission Tomography (PET): PET Or CT Imaging; PET Or MRI Imaging
• Companies Mentioned: Cardinal Health; General Electric; Bayer AG; Novartis AG; Siemens Healthineers AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Cancer Nuclear Medicine Diagnostics Market Characteristics

3. Prostate Cancer Nuclear Medicine Diagnostics Market Trends And Strategies

4. Prostate Cancer Nuclear Medicine Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Prostate Cancer Nuclear Medicine Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prostate Cancer Nuclear Medicine Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prostate Cancer Nuclear Medicine Diagnostics Market Growth Rate Analysis
• 5.4. Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prostate Cancer Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prostate Cancer Nuclear Medicine Diagnostics Total Addressable Market (TAM)

6. Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation

• 6.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Photon Emission Computed Tomography (SPECT)
• Photon Emission Computed Tomography (PET)
• 6.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preliminary Tests
• Confirmatory Tests
• 6.3. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.4. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation Of Single Photon Emission Computed Tomography (SPECT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gamma Camera SPECT
• Hybrid SPECT Or CT Imaging
• 6.5. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation Of Positron Emission Tomography (PET), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PET Or CT Imaging
• PET Or MRI Imaging

7. Prostate Cancer Nuclear Medicine Diagnostics Market Regional And Country Analysis

• 7.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market

• 8.1. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate Cancer Nuclear Medicine Diagnostics Market

• 9.1. China Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 9.2. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate Cancer Nuclear Medicine Diagnostics Market

• 10.1. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate Cancer Nuclear Medicine Diagnostics Market

• 11.1. Japan Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 11.2. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate Cancer Nuclear Medicine Diagnostics Market

• 12.1. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market

• 13.1. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market

• 14.1. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 14.2. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market

• 15.1. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 15.2. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate Cancer Nuclear Medicine Diagnostics Market

• 16.1. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate Cancer Nuclear Medicine Diagnostics Market

• 17.1. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate Cancer Nuclear Medicine Diagnostics Market

• 18.1. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate Cancer Nuclear Medicine Diagnostics Market

• 19.1. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate Cancer Nuclear Medicine Diagnostics Market

• 20.1. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market

• 21.1. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 21.2. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate Cancer Nuclear Medicine Diagnostics Market

• 22.1. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate Cancer Nuclear Medicine Diagnostics Market

• 23.1. North America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 23.2. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate Cancer Nuclear Medicine Diagnostics Market

• 24.1. USA Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 24.2. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate Cancer Nuclear Medicine Diagnostics Market

• 25.1. Canada Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 25.2. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate Cancer Nuclear Medicine Diagnostics Market

• 26.1. South America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 26.2. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market

• 27.1. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market

• 28.1. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 28.2. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate Cancer Nuclear Medicine Diagnostics Market

• 29.1. Africa Prostate Cancer Nuclear Medicine Diagnostics Market Overview
• 29.2. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape
• 30.2. Prostate Cancer Nuclear Medicine Diagnostics Market Company Profiles
  • 30.2.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. General Electric Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Prostate Cancer Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

• 31.1. GE Healthcare
• 31.2. Lantheus
• 31.3. CURIUM PHARMA
• 31.4. Telix Pharmaceuticals Ltd.
• 31.5. Eckert & Ziegler AG
• 31.6. Point Biopharma Global Inc.
• 31.7. Point Biopharma
• 31.8. Alliance Medical Ltd.
• 31.9. SHINE Medical Technologies LLC
• 31.10. PETNET Solution
• 31.11. NorthStar Medical Radioisotopes LLC
• 31.12. Global Medical Solutions LLC
• 31.13. Isotope Technologies Garching (ITG)
• 31.14. Jubilant Pharma Limited
• 31.15. Blue Earth Diagnostics Inc.

32. Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate Cancer Nuclear Medicine Diagnostics Market

34. Recent Developments In The Prostate Cancer Nuclear Medicine Diagnostics Market

35. Prostate Cancer Nuclear Medicine Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Prostate Cancer Nuclear Medicine Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prostate Cancer Nuclear Medicine Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prostate Cancer Nuclear Medicine Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer